Precision Biosciences 3Q 2026: Revenue $0 Net loss $7.6M, EPS $(0.28) — 10-Q Summary
Precision Biosciences reported 3Q 2026 revenue of $0, down from $13K a year ago, and a net loss of $7.6M, improved from $21.8M. EPS was $(0.28). Nine-month revenue was $10.8M, driven by partnerships. Clinical trials for PBGENE-HBV, PBGENE-DMD, and other programs progressed.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh data on revenue, loss, and trial progress, offering traders a basis to reassess valuation and risk.
Market read
Micro‑cap biotech earnings with modest loss improvement; relevance mainly to biotech specialists and risk‑averse traders.
What to watch
Non‑cash warrant gains mask underlying cash‑flow weakness; upcoming Phase 2 dosing data could materially shift sentiment.
Background
Precision Biosciences (DTIL) is a clinical‑stage gene‑editing company. The filing reports its third‑quarter 2026 financials and trial updates.
Ticker impact
Precision Biosciences filed its Q3 2026 10‑Q showing $0 revenue and a narrowed net loss of $7.6 M versus $21.8 M a year ago.
modest downside as investors weigh continued losses against narrowing loss margin
Losses remain sizable; however, the reduction in loss and zero revenue highlight ongoing cash‑burn concerns, likely limiting upside.
Market effects
Highlights continued volatility in the gene‑editing biotech sector as small caps report minimal revenue and ongoing cash burn.
Limited to U.S. biotech investors; no broader regional effect.
Low global impact; primarily relevant to niche biotech and specialty investors.
Counterpoint
The narrowing loss could be seen as a turning point, suggesting a potential rebound if upcoming trial data are positive.
Key entities
- companyPrecision Biosciences
Clinical‑stage gene‑editing biotech (ticker DTIL).
- partnerTG Therapeutics
Collaboration partner contributing to nine‑month revenue.
